浙江尖峰集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的控股子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局核准签发的 盐酸莫西沙星滴眼液《药品注册证书》（证书编号：2023S01585、2023S01586）， 现将相关情况公告如下： 一、化学仿制药的基本情况 药品名称：盐酸莫西沙星滴眼液 剂型：眼用制剂 规格：0.5%（3ml：15mg，按 C₂₁H24FN3O₄计） 0.5%（5ml：25mg，按 C₂₁H24FN3O₄计） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 证券代码：600668 证券简称：尖峰集团 编号：临 2023-026 药品注册标准编号：YBH14742023 药品有效期：24 个月 药品批准文号：国药准字 H20234300、国药准字 H20234301 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2023-025 浙江尖峰集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的控股子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局核准签发的 甲磺酸仑伐替尼胶囊《药品注册证书》（证书编号：2023S01465），现将相关情况 公告如下： 一、化学仿制药的基本情况 药品名称：甲磺酸仑伐替尼胶囊 剂型：胶囊剂 规格：4mg（按 C₂₁H₁₉ClN₄O₄计） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 药品上市许可持有人：浙江尖峰药业有限公司 1 本次尖峰药业获得甲磺酸仑伐替尼胶囊《药品注册证书》，标志着尖峰药 业具有进行该药品生产，销售的资格，将进一步丰富尖峰药业的产品种 类，有助于提升公司医药业务的竞争力。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投产的周期长、 ...

证券代码：600668 证券简称：尖峰集团 公告编号：2023-024 浙江尖峰集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二） 会议召开地点：上证路演中心 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 09 月 22 日(星期五) 至 09 月 28 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 jfjtsmh@126.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 浙江尖峰集团股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 10 月 09 日 下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投 资者关心的问题进行交流。 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2023-023 浙江尖峰集团股份有限公司 关于子公司获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙 江尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局关于吗 替麦考酚酯胶囊的《药品补充申请批准通知书》（通知书编号：2023B04552），现 将相关情况公告如下： 一、化学原料药的基本情况 药品名称：吗替麦考酚酯胶囊 剂型：胶囊剂 规格：0.25g 包装规格：10 粒/板×4 板/盒 原药品批准文号：国药准字 H20070267 药品注册标准编号：YBH13972023 上市许可持有人：浙江尖峰药业有限公司 生产企业：浙江尖峰药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗 本品与皮质类固醇以及环孢素或他克莫司同时应用，适用于治疗：接受同种 异体肾脏移植的患者中预防器官排斥反应；接受同种异体肝脏移植的患者 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2023-022 浙江尖峰集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）全资子公司浙江 尖峰药业有限公司的控股子公司安徽尖峰北卡药业有限公司（以下简称"尖峰北 卡"）收到国家药品监督管理局关于化学原料药盐酸莫西沙星的《化学原料药上 市申请批准通知书》（通知书编号：2023YS00595），现将相关情况公告如下： 三、对公司的影响及风险提示 一、化学原料药的基本情况 化学原料药名称：盐酸莫西沙星 包装规格：2kg/袋 通知书编号：2023YS00595 登记号：Y20210000527 化学原料药注册标准编号：YBY67312023 生产企业名称：安徽尖峰北卡药业有限公司 生产企业地址：安徽东至经济开发区 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 1 本次尖峰北卡获得化学原料药盐酸莫西沙星的《化学原料药上市申 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 138,118.63 million, a decrease of 21.65% compared to CNY 176,275.55 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2023 was CNY 11,162.18 million, down 22.74% from CNY 14,448.32 million year-on-year[18]. - The net cash flow from operating activities was CNY 2,756.54 million, representing a significant decline of 85.04% compared to CNY 18,426.82 million in the previous year[18]. - Basic earnings per share for the first half of 2023 were CNY 0.3244, down 22.74% from CNY 0.4199 in the same period last year[19]. - The weighted average return on equity decreased to 2.13%, down 0.63 percentage points from 2.76% in the previous year[19]. - Cement sales volume reached 2.5073 million tons, representing a decline of 5.26% year-on-year[34]. - The company achieved a revenue of 1.38 billion RMB in the first half of 2023, a decrease of 21.65% year-on-year[33]. - The net profit attributable to shareholders was 112 million RMB, down 22.74% compared to the previous year[33]. - The company reported a net loss for the same period was CNY 2,400,061,020, indicating a challenging financial environment[124]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 722,627.33 million, a decrease of 1.29% from CNY 732,060.34 million at the end of the previous year[18]. - The net assets attributable to shareholders at the end of the reporting period were CNY 519,106.66 million, showing a slight increase of 0.11% from CNY 518,560.53 million at the end of the previous year[18]. - Total assets at the end of the reporting period amounted to 721,000 million, with cash and cash equivalents decreasing by 21.09% to 29,447.17 million[39]. - Long-term equity investments stood at 187,497.36 million, a slight decrease of 0.78% compared to the previous year, attributed to changes in the net assets of investee companies[42]. - The total liabilities decreased to CNY 1,390,616,997.52 as of June 30, 2023, compared to CNY 1,432,427,056.41 at the end of 2022[104]. Cash Flow - The net cash flow from operating activities plummeted by 85.04% to 2,756.54 million, primarily due to a decrease in cash inflows from subsidiary operations[38]. - The net cash flow from investing activities improved to -15,741.48 million from -26,778.50 million, mainly due to a reduction in cash paid for external investments[38]. - The net cash flow from financing activities decreased by 86.51% to 5,170.35 million, largely due to the repayment of maturing bank loans during the reporting period[38]. - The net cash flow from operating activities for the first half of 2023 was 27,565,398.90 RMB, a decrease of 85% from 184,268,217.59 RMB in the same period of 2022[114]. - Cash inflow from financing activities decreased to ¥356,203,037.13 in H1 2023 from ¥442,000,000.00 in H1 2022, a decline of approximately 19.4%[116]. Business Operations - The company's main business remains focused on building materials and pharmaceuticals, with cement and drugs as the primary products[23]. - The company has established three new dry-process cement production lines in its subsidiaries, enhancing production capacity and operational efficiency[24]. - The company is expanding its pharmaceutical product lines to include anti-tumor drugs and pediatric medications[23]. - The company is actively pursuing a cost leadership strategy in its cement business, focusing on management innovation and energy-saving measures[24]. - The company is involved in the national drug centralized procurement process, which includes 40 drug varieties across various treatment areas[28]. Research and Development - The company has over 20 R&D projects in various stages, including clinical trials and production applications, ensuring product development in the pharmaceutical sector[32]. - The company launched new products, including Valsartan Amlodipine Tablets and a chemical raw material, further expanding its product line[35]. - R&D expenses decreased by 5.21% to 5,518.76 million from 5,822.37 million, indicating a reduction in investment in research and development activities[38]. Environmental Compliance - The company is committed to environmental sustainability by adopting new production technologies and establishing a comprehensive environmental management system[57]. - The company has established long-term partnerships with coal suppliers to manage procurement costs effectively[54]. - The company’s emissions for sulfur dioxide and nitrogen oxides from its key pollutant discharge units were below the regulatory limits, with specific values reported for each unit[64]. - The company has implemented repairs on wastewater treatment facilities and increased self-monitoring frequency to ensure compliance with discharge standards[71]. - The company has actively conducted environmental education and training to enhance environmental protection efforts across non-key pollutant discharge units[72]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 39,452[91]. - The largest shareholder, Jinhua Tongji State-owned Assets Investment Co., Ltd., holds 55,564,103 shares, representing 16.15% of the total shares[93]. - The total number of shares and capital structure of the company remained unchanged during the reporting period[91]. - The company reported no profit distribution or capital reserve transfer plans for the half-year period[61]. Risk Management - The company aims to mitigate risks from economic cycles by diversifying into health products and logistics[53]. - The company is facing risks from energy price fluctuations, particularly in coal and electricity, which significantly impact production costs[54]. - The company is enhancing its internal control systems and management practices to address operational risks associated with its diverse business segments[56]. Corporate Governance - The company has committed to maintaining its independence and avoiding conflicts of interest with its controlling shareholders, ensuring fair practices in its operations[80]. - The company has implemented a long-term incentive management plan to stabilize and motivate key employees and management personnel[62]. - The company held its annual general meeting on May 18, 2023, where resolutions including the approval of the 2022 annual financial report were passed[60].

证券代码：600668 证券简称：尖峰集团 编号：临2023-017 浙江尖峰集团股份有限公司 关于控股子公司产品抽检不合格情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 国家药品监督管理局（以下简称"国家药监局"）于2023年8月18日发布《国家 药监局关于14批次药品不符合规定的通告（2023年第 36号）》，其中浙江尖峰集团股 份有限公司（以下简称"本公司"）的控股子公司浙江尖峰药业有限公司（以下简称 "尖峰药业"）生产的盐酸奥洛他定滴眼液（批号：211206）装量检验不符合规定。 现将有关情况公告如下： 一、该批次产品基本信息 三、 对公司的影响 产品名称：盐酸奥洛他定滴眼液；批号：211206；规格：0.1%(5ml:5mg,以 C21H23NO3计)；检验结果：装量不合格；检验依据：国家药品监督管理局标准 YBH00792019；检品来源：重庆医药（集团）新疆有限公司；生产企业：浙江尖峰药 业有限公司。 二、公司对该批次产品的核查和采取的措施 尖峰药业上述批号产品的生产日期为2021年12月10日 ...

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 第一季度财务报表是否经审计 □是√否 2023 年第一季度报告 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 证券代码：600668 证券简称：尖峰集团 浙江尖峰集团股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 2 / 12 2023 年第一季度报告 1 / 12 一、 主要财务数据 (一)主要会计数据和财务指标 2023 年第一季度报告 | | 本报告期末 | 上年度末 | | 本报告期末比 上年度末增减 | | --- | --- | --- | --- | --- | | | | | | 变动幅度(%) | | 总资产 | 715,659.66 | | 732,060.34 | -2.24 | | 归属于上市公司股东的 | 520,614.50 | | 51 ...

证券代码：600668 证券简称：尖峰集团 公告编号：2023-011 浙江尖峰集团股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 21 日(星期五) 至 04 月 27 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jfjtsmh@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 浙江尖峰集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日发 布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营 成果、财务状况，公司计划于 2023 年 04 月 28 日下午 16:00-17:00 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明 ...

Financial Performance - In 2022, the company's operating revenue was CNY 356,039.41 million, a decrease of 6.43% compared to CNY 380,503.81 million in 2021[21]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 28,772.04 million, down 68.86% from CNY 92,407.89 million in 2021[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 11,127.43 million, a decline of 82.47% compared to CNY 63,464.71 million in 2021[21]. - The net cash flow from operating activities for 2022 was CNY 38,333.03 million, a decrease of 19.36% from CNY 47,535.01 million in 2021[21]. - As of the end of 2022, the net assets attributable to shareholders were CNY 518,560.53 million, a slight decrease of 0.41% from CNY 520,703.62 million at the end of 2021[21]. - The total assets at the end of 2022 were CNY 732,060.34 million, an increase of 4.22% compared to CNY 702,443.51 million at the end of 2021[21]. - Basic earnings per share were 0.8362 RMB, reflecting a decline of 68.86% from 2.6856 RMB in 2021[22]. - The weighted average return on equity decreased to 5.55%, down from 19.32% in 2021, a drop of 13.77 percentage points[22]. Business Operations - Cement sales volume was 5.7067 million tons, a decrease of 12.23% year-on-year due to weak market demand[29]. - The company established Yunnan Jianfeng New Building Materials Co., Ltd. to enhance its supply chain and expand its business[29]. - The company invested 133 million RMB to increase its stake in a subsidiary, making it a controlling entity[29]. - The company’s cement subsidiaries implemented benchmark management and cost control measures, successfully maintaining production and sales balance despite market downturns[30]. - The company’s pharmaceutical division made progress in innovation, with the annual production capacity of solid preparations reaching 2 billion tablets, and several products entering the registration phase[31]. - The company is exploring market expansion opportunities in the Shanghai region, where revenue increased by 24.98% to CNY 47,607.77 million[50]. Industry Challenges - The cement industry faced significant challenges in 2022, with national real estate development investment declining by 10.0% year-on-year to CNY 13.29 trillion, and cement production dropping by 10.8% to 2.118 billion tons, the lowest in nearly a decade[33]. - The pharmaceutical sector reported a revenue of CNY 2.91 trillion, a year-on-year decrease of 1.6%, with total profits down by 31.8% to CNY 428.87 billion[34]. - The pharmaceutical sector is experiencing increased competition due to policies like centralized procurement, leading to reduced drug prices and profitability[121]. Research and Development - Research and development expenses increased by 22.91% to 122 million RMB[46]. - The company has over 20 R&D projects in various stages, including clinical research and production preparation[42]. - The company aims to enhance its R&D capabilities by leveraging platforms such as the Academician Expert Workstation and Zhejiang New Drug R&D Center[83]. - The company is advancing its "4+2" new product development strategy, focusing on anti-infection, cardiovascular, anti-tumor, and pediatric medications[82]. Environmental Initiatives - The company’s green initiatives led to its inclusion in the national list of green factories for 2022, reflecting its commitment to sustainable practices[30]. - The company has committed to reducing VOC emissions through regular third-party LDAR assessments at its facilities[175]. - The company has successfully completed the ultra-low emission transformation project, achieving particulate matter emissions that meet ultra-low standards[175]. - The company has implemented pollution control facilities with a design capacity of 800,000 m³/h for SO2 and NOX emissions at various plants, all operating normally[169]. Corporate Governance - The company held 6 board meetings and 1 shareholders' meeting during the reporting period, ensuring diligent decision-making and compliance with governance regulations[127]. - The supervisory board conducted 5 meetings, focusing on financial oversight and protecting shareholder rights[128]. - The company maintained complete operational independence from its controlling shareholder, with no asset occupation or financial dependency reported[128]. - The company has established a transparent information disclosure system, with no regulatory penalties for disclosure violations during the reporting period[128]. Future Outlook - The company aims to achieve a sales revenue target of 4 billion yuan in 2023, with continuous improvement in financial and economic indicators[114]. - The cement segment is expected to stabilize demand in 2023 due to supportive infrastructure investments and real estate policies, following a challenging 2022[110]. - The pharmaceutical sector will focus on innovation and quality as core competitive advantages, adapting to ongoing policy changes in drug procurement and pricing[111]. - Significant investments will be made in R&D to advance clinical studies for products like JFAN-1001 and expedite production registration for existing products[116].